Sight SciencesSGHT +0.18%72 EBIT per Share is $-0.61 as of Mar. 2026. GuruFocus rates SGHT with a GF Score™ of 72/100 and a GF Value™ of $4.50 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 691 Medical Devices & Instruments companies, Sight Sciences ranks better than 71.35% on this metric.
Sight Sciences's EBIT per Share for the
three
months ended in Mar. 2026 was $-0.22.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.61.
During the past 3 years, the average EBIT per Share Growth Rate was 26.00% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 9.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Sight Sciences's EBIT per Share or its related term are showing as below:
SGHT'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -63.1 Med: -8.7 Max: 26
Current: 26
During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of Sight Sciences was 26.00% per year. The lowest was -63.10% per year. And the median was -8.70% per year.
SGHT's 3-Year EBIT Growth Rate is ranked better than 71.35% of 691
companies
in the Medical Devices & Instruments industry
Industry Median: 9.6
vs SGHT: 26.00
Sight Sciences's EBIT for the
three
months ended in Mar. 2026 was $-11.70 Mil.
Sight Sciences (NAS:SGHT) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Sight Sciences EBIT per Share Related Terms
Sight Sciences EBIT per Share Historical Data
* Premium members only.
The historical data trend for Sight Sciences's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.61
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sight Sciences (SGHT) has a EBIT per Share of $-0.61 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Sight Sciences and its competitors. According to the industry distribution chart, Sight Sciences ranks #198 out of 691 companies in the Medical Devices & Instruments industry, placing it in the top 28.7%.
Is Sight Sciences' EBIT per Share too high?
Sight Sciences' current EBIT per Share is $-0.61. Based on the distribution chart, Sight Sciences ranks #198 out of 691 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Sight Sciences has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sight Sciences' EBIT per Share compare to SENS and LAB?
According to the Medical Devices & Instruments industry distribution chart, Sight Sciences ranks #198 out of 691 companies for EBIT per Share. This puts Sight Sciences in the upper half of its industry. The industry median EBIT per Share is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.60, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Sight Sciences and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sight Sciences's current EBIT per Share is $-0.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sight Sciences stock overvalued right now?
Based on GuruFocus' analysis, Sight Sciences (SGHT) is currently considered Modestly Overvalued. The stock's GF Value™ is $4.50, compared to a current price of $5.45 — trading 21.1% above its estimated fair value. The current EBIT per Share is $-0.61. Sight Sciences' overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Sight Sciences (SGHT), the current EBIT per Share is $-0.61 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sight Sciences (SGHT) Overvalued in 2026?
Based on GuruFocus' analysis, Sight Sciences stock appears to be overvalued.
The current stock price of $5.45 is trading 21.1% above its estimated GF Value™ of $4.50.
GuruFocus considers Sight Sciences to be Modestly Overvalued.
Key valuation signals for SGHT:
EBIT per Share: $-0.61
GF Value™: $4.50 vs. price of $5.45 (21.1% above fair value)
No single metric tells the full story. See the SGHT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
72GF Score
Get the complete analysis for SGHT
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGHT has been successfully added to your 
